Johnson & Johnson Consumer Inc. announced today that it has entered into a definitive agreement to acquire NeoStrata Company, Inc., a global leader in dermocosmetics.
The acquisition will include NeoStrata’s affiliates and parent company TriStrata, Incorporated, a privately-held company. Financial terms were not disclosed.
NeoStrata, based in Princeton, N.J., has a history of innovation that includes breakthrough research in Alpha hydroxy acids, which have become a standard among anti-aging technologies in the beauty category. The Company develops and markets a range of clinically-proven, dermatologist-developed, skin care products that meet the needs of every skin type.
“Drs. Ruey Yu and Eugene Van Scott formed NeoStrata in 1988 and continue to make significant contributions to the science of skincare. NeoStrata’s legacy in dermocosmetics will complement our global Consumer portfolio and enable us to deliver advanced skin care brands to consumers around the world,” said Jorge Mesquita, Worldwide Chairman, Consumer, Johnson & Johnson. “NeoStrata and Johnson & Johnson share a strong history of innovation and together we will work to discover important new skin care solutions grounded in deep human insights and compelling science. We look forward to working closely with NeoStrata’s distributors around the world and having their outstanding team of employees join Johnson & Johnson Consumer later this year.”
The acquisition is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions and expected to close in the first half of 2016.
Source: Johnson & Johnson
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
